Investor Presentaiton
Safety/Tolerability with Rigosertib + Nivolumab
Treatment related adverse events were mostly mild
Urinary toxicities well documented
with rigosertib were most common
TRAE
• TRAES were mostly mild and
manageable
No synergistic toxicities noted for
either study drug
One DLT at 560mg BID for grade 3
hyponatremia - previously
documented with rigosertib
Entire Cohort: N=19
Treatment-Related Adverse Events (TRAES) - n (%)
Grade 1-2
Grade 3
•
10 (53)
Dysuria
12 (63)
Hematuria
Urinary Frequency
5 (26)
6 (32)
Abdominal Pain
10 (53)
Fatigue
13 (68)
Anemia
Lymphopenia
4 (21)
1(5)
2 (11)
Thrombocytopenia
2 (11)
Hyponatremia*
7 (37)
1(5)*
Hyperglycemia
11 (58)
•
AST elevation
4 (21)
1 (5)#
ALT elevation
3 (16)
1 (5)#
ALK elevation
6 (32)
Nausea/Vomiting
Constipation
5 (26)
1(5)
7 (37)
3 (16)
Diarrhea
6 (32)
1(5)
Anorexia
Acute Kidney Injury
7 (37)^
Infusion-related Reaction
1 (5)
*Dose Limiting Toxicity: #Resolved with steroids: "Resolved with IV fluids
Adapted from Veluswamy et al. European Society for Medical Oncology Congress 2022. TRAE: Treatment related adverse event; DLT: Dose limiting toxicity
11
0
ONCONOVA
THERAPEUTICSView entire presentation